The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges - 16/04/21
pages | 18 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Lung cancer is one of the common malignant tumors that threaten human life with serious incidence and high mortality. According to the histopathological characteristics, lung cancer is mainly divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for about 80–85% of lung cancers. In fact, lung cancer metastasis is a major cause of treatment failure in clinical patients. The underlying reason is that the mechanisms of lung cancer metastasis are still not fully understood. The metastasis of lung cancer cells is controlled by many factors, including the interaction of various components in the lung cancer microenvironment, epithelial-mesenchymal transition (EMT) transformation, and metastasis of cancer cells through blood vessels and lymphatics. The molecular relationships are even more intricate. Further study on the mechanisms of lung cancer metastasis and in search of effective therapeutic targets can bring more reference directions for clinical drug research and development. This paper focuses on the factors affecting lung cancer metastasis and connects with related molecular mechanisms of the lung cancer metastasis and mechanisms of lung cancer to specific organs, which mainly reviews the latest research progress of NSCLC metastasis. Besides, in this paper, experimental models of lung cancer and metastasis, mechanisms in SCLC transfer and the challenges about clinical management of lung cancer are also discussed. The review is intended to provide reference value for the future research in this field and promising treatment clues for clinical patients.
Le texte complet de cet article est disponible en PDF.Highlights |
• | This paper reviews recent researches on lung cancer metastasis. |
• | The influencing factors, molecular mechanisms and specific metastasis of lung cancer are summarized. |
• | Many factors can be regarded as potential targets in the diagnosis and treatment of lung cancer. |
Abbreviations : ATP6V0d2, APP, ANGPTL4, AKR1C1, ATF4, ALK, BBB, BsAb-5, BACH1, BTBD9, BMICs, CAFs, CD, c-MET, CTLA-4, circRNA, CCND1, DR6, CypA, CXCL, CXCR, CELSR1, ceRNA, CDK, CRTC, CADM, CIC, CEMIP, CUL5, DHX15, DNA-PKcs, EMT, ERK, ECM, ELF3, EGFR, ETS-1, FBP1, EGFR-TKIs, FGF, FOXM1, FSCN1, FOXP, FGFR, FMNL1, FAK, Fra-1, GBE1, GSK-3β, GFPT2, GLK, GATA6, GRIA3, HIF, HOPX, HGF, HtrA3, HOXA-AS2, HOXD8, HDAC, IL, IGF2, IQGAP1, ICIs, JAK2, JPX, JHDM1D-AS1, KLF3, KEAP1, KRAS, KHSRP, LCSCs, LUAD, lncRNA, IFN-γ, LSCC, LIGHT-VTP, LSECs, MMP, MEK, mTOR, MAPK, MICA, miRNA, MAD2B, MALAT1, MAP3K2, MTA2, NSCLC, NKX2–1, ncRNAs, NF-κB, NK, NEK4, NONO, NRF2, NFIB, NKG2DL, PI3K, PKB, PD-L, p53, PTEN, PECAM1, PPWD1, PCAT6, PGK1, PD-1, QKI-5, RANK/RANKL/OPG, SCLC, STAT, sEVs, Smad, SPRY4, SQCLC, SOX2, SPOCK1, S100A16, Sema4D, SOCS3, SRC, TGF-β1, TME, TAM, TFEB, Th, TNC, TRIM, TPPP3, TACSTD2, TXNIP, TIM-4, TSPAN12, TP53, TNFAIP1, T790M, UGDH, UDP-Glc, VEGF, VCAM-1, VAMP3, VEGFR, vWF, VE-cadherin, WDFY2, YAP1, ZEB2-AS1
Keywords : Lung cancer, Metastasis, Therapeutic challenges, Influencing factors, Molecular mechanisms
Plan
Vol 138
Article 111450- juin 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?